|Articles|January 12, 2016
Certara Launches Consulting in China
Move helps biosimulation consulting support for clients in China, as well as support China's expansion of its fast-track drug approval process.
Advertisement
Certara®, a global biosimulation technology-enabled drug development company, announced the launch of Certara Strategic Consulting China in Shanghai. The new company will be led by President and CEO Christine Yuying Gao, MD, PhD, former vice president of consulting services at Quantitative Solutions, a global pharmacometrics consulting company. Quantitative Solutions merged with Certara’s Pharsight Consulting Services in July 2015 to form Certara Strategic Consulting.
Read the full
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
ACT Brief: RBQM Financial Value Quantified, Sponsor-Configurable AI Systems, and Basket Trials for Rare Pediatrics
2
Quantifying the Net Financial Value of Deploying Risk-Based Quality Management
3
ACT Brief: Enterprise Risk Management, Execution Architecture for AI, and Rare Pediatric Regulatory Support
4
ACT Brief: Data Pipeline Fragmentation, Vaccine Trial Pressures, and BTK Degrader Partnership
5